|
1
|
Koumaki D, Kostakis G, Koumaki V, et al:
Novel mutations of the HRAS gene and absence of hotspot mutations
of the BRAF genes in oral squamous cell carcinoma in a Greek
population. Oncol Rep. 27:1555–1560. 2012.PubMed/NCBI
|
|
2
|
Feller L and Lemmer J: Oral squamous cell
carcinoma: epidemiology, clinical presentation and treatment. J
Cancer Ther. 3:263–268. 2012. View Article : Google Scholar
|
|
3
|
Petti S: Lifestyle risk factors for oral
cancer. Oral Oncol. 45:340–350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scully C and Bagan J: Oral squamous cell
carcinoma overview. Oral Oncol. 45:301–308. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sen B, Peng S, Saigal B, Williams MD and
Johnson FM: Distinct interactions between c-Src and c-Met in
mediating resistance to c-Src inhibition in head and neck cancer.
Clin Cancer Res. 17:514–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murugan AK, Munirajan AK and Tsuchida N:
Ras oncogenes in oral cancer: the past 20 years. Oral Oncol.
48:383–392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blume-Jensen P and Hunter T: Oncogenic
kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rimkunas VM, Crosby KE, Li D, et al:
Analysis of receptor tyrosine kinase ROS1-positive tumors in
non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Clin Cancer Res. 18:4449–4457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Acquaviva J, Wong R and Charest A: The
multifaceted roles of the receptor tyrosine kinase ROS in
development and cancer. Biochim Biophys Acta. 1795:37–52.
2009.PubMed/NCBI
|
|
10
|
Gu TL, Deng X, Huang F, et al: Survey of
tyrosine kinase signaling reveals ROS kinase fusions in human
cholangiocarcinoma. PLoS One. 6:e156402011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee HJ, Seol HS, Kim JY, et al: ROS1
receptor tyrosine kinase, a druggable target, is frequently
overexpressed in non-small cell lung carcinomas via genetic and
epigenetic mechanisms. Ann Surg Oncol. 20:200–208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bergethon K, Shaw AT, Ou SH, et al: ROS1
rearrangements define a unique molecular class of lung cancers. J
Clin Oncol. 30:863–870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
El-Deeb IM, Yoo KH and Lee SH: ROS
receptor tyrosine kinase: a new potential target for anticancer
drugs. Med Res Rev. 31:794–818. 2011.PubMed/NCBI
|
|
14
|
Davies KD and Doebele RC: Molecular
pathways: ROS1 fusion proteins in cancer. Clin Cancer Res.
19:4040–4045. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lo Muzio L, Leonardi R, Mignogna MD, et
al: Scatter factor receptor (c-Met) as possible prognostic factor
in patients with oral squamous cell carcinoma. Anticancer Res.
24:1063–1069. 2004.PubMed/NCBI
|
|
16
|
Maeda T, Matsumura S, Hiranuma H, et al:
Expression of vascular endothelial growth factor in human oral
squamous cell carcinoma: its association with tumour progression
and p53 gene status. J Clin Pathol. 51:771–775. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lim J, Kim JH, Paeng JY, et al: Prognostic
value of activated Akt expression in oral squamous cell carcinoma.
J Clin Pathol. 58:1199–1205. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smith BD, Smith GL, Carter D, Sasaki CT
and Haffty BG: Prognostic significance of vascular endothelial
growth factor protein levels in oral and oropharyngeal squamous
cell carcinoma. J Clin Oncol. 18:2046–2052. 2000.PubMed/NCBI
|
|
19
|
Roland NJ, Caslin AW, Nash J and Stell PM:
Value of grading squamous cell carcinoma of the head and neck. Head
Neck. 14:224–229. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akhter M, Hossain S, Rahman QB and Molla
MR: A study on histological grading of oral squamous cell carcinoma
and its co-relationship with regional metastasis. J Oral Maxillofac
Pathol. 15:168–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sobin L, Gospodarowicz M and Wittekind C:
TNM Classification of Malignant Tumors. 7th. Wiley-Blackwell;
Oxford: 2009
|
|
22
|
Mrena J, Wiksten JP, Thiel A, et al:
Cyclooxygenase-2 is an independent prognostic factor in gastric
cancer and its expression is regulated by the messenger RNA
stability factor HuR. Clin Cancer Res. 11:7362–7368. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen JM, Heller D, Poon B, Kang L and Wang
LH: The proto-oncogene c-ros codes for a transmembrane tyrosine
protein kinase sharing sequence and structural homology with
sevenless protein of Drosophila melanogaster. Oncogene. 6:257–264.
1991.PubMed/NCBI
|
|
24
|
Charest A, Kheifets V, Park J, et al:
Oncogenic targeting of an activated tyrosine kinase to the Golgi
apparatus in a glioblastoma. Proc Natl Acad Sci USA. 100:916–921.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eom M, Lkhagvadorj S, Oh SS, Han A and
Park KH: ROS1 expression in invasive ductal carcinoma of the breast
related to proliferation activity. Yonsei Med J. 54:650–657. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mapstone T, McMichael M and Goldthwait D:
Expression of platelet-derived growth factors, transforming growth
factors and the ros gene in a variety of primary human brain
tumors. Neurosurgery. 28:216–222. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jun HJ, Johnson H, Bronson RT, et al: The
oncogenic lung cancer fusion kinase CD74-ROS activates a novel
invasiveness pathway through E-Syt1 phosphorylation. Cancer Res.
72:3764–3774. 2012. View Article : Google Scholar : PubMed/NCBI
|
